Life Sciences Radar
The radar compares what 25 large pharma and biotech R&D spenders say in public about two things: AI and computation in drug discovery, and the digitalisation of their research labs and scientific data. Each company gets two scores for each theme. Priority is how much weight the company puts on the theme in its own disclosures, on a scale of 1 to 10. Delivery is how far its published evidence shows the work running, from 0 to 10. Open any company to see the quotes and links behind its scores.
Beside the scores sits observed activity: commitments the company made public in the last 12 months, such as partnerships, compute and new research units, and the R&D roles open on its job site on 6 October 2026. Activity is a count of public signals, not a score, and it never changes Priority or Delivery. A company with fresh commitments and open roles but a low Delivery score is one to look into.
The scores come only from public information published up to 5 October 2026. They are Ortent's assessment and have not been independently validated. A low score can mean a company says little in public, or that we could not reach some of its sources, so the coverage status sits next to every score. If you know of public information we missed, report it at the foot of the page and we will review it at the next quarterly refresh.
Rochescaled
Priority 8 / Delivery 7
Observed activity: 4 new · 24 roles
Priority 8: what the company says
Revolutionizing drug R&D with Lab-in-a-Loop Aviv Regev, Head of Genentech Research and Early Development (gRED)Roche Pharma Day 2026 presentation, 28 Sep 2026, p. 5Our ‘R&D Excellence’ initiative, launched two years ago to accelerate our research and development, is showing strong progress.Roche Annual Report 2025, 29 Jan 2026, p. 12Evolve our R&D engine and invest in its excellence Ongoing R&D investments Boston Innovation Center focusing on CVRM and AI in drug development openedRoche Pharma Day 2026 presentation, 28 Sep 2026, p. 62Delivery 7, scaled: what it shows running
Pathobiology maps have scaled and accelerated our pipeline Example: IBD pathobiology mapsRoche Pharma Day 2026 presentation, 28 Sep 2026, p. 76BRAID (biology AI) PrescientDesign (antibodies AI) gRED Computational Sciences (gCS) consolidated ... Recursion collaboration ... NVIDIA partnership OpenAI pilot partnership AI factory (NVIDIA)Roche Pharma Day 2026 presentation (London, 28 September 2026), 28 Sep 2026, p. 71AI-enhanced pathobiology maps across our TAs ... +155% First map deployed (IBD) 4 neurology maps deployed increase in LI entries in 2 yearsRoche Pharma Day 2026 presentation, 28 Sep 2026, p. 77Commitments made public in the last 12 months: 4
- Earendil Labs bispecific antibody discovery collaboration New, announced, 24 Sep 2026, source: partner release, company quoted
- NVIDIA collaboration and hybrid-cloud AI factory Expanded, operational, 16 Mar 2026, source: company
- Computational Sciences Center of Excellence (CSCoE) New, operational, 9 Jan 2026, source: company
- Medra physical AI lab collaboration New, operational, 11 Dec 2025, source: company
Prior 12 months: 2. Search coverage: partial.
R&D roles open on 6 Oct 2026: 24
- Machine Learning Engineer/Senior Machine Learning Engineer - Devops, AI for Drug Discovery New York City, New York, United States of America
- Machine Learning Scientist, Scientific Reasoning Models, AI for Drug Discovery New York City, New York, United States of America
- Senior / Principal Machine Learning Scientist, Scientific Reasoning Models, AI for Drug Discovery New York City, New York, United States of America
- Senior Machine Learning Engineer - AI Enablement Welwyn, Hertfordshire, United Kingdom
- Senior/Principal Machine Learning Scientist, Perturbation Biology, AI Biology & Translation (AIBT) South San Francisco, California, United States of America
- Machine Learning Scientist - Quantum Chemistry Basel, Basel-City, Switzerland
and 18 more in the company brief.
Technology named in these postings
Named as in use: AWS, Kubernetes, Terraform, PyTorch
Asked for as experience: Helm, LangGraph
Showing up to three quotes for each score. Observed activity is a count of public signals, not a score, and search coverage varies by company. The full account brief for Roche lists every source.
Eli Lillylive
Priority 8 / Delivery 4
Observed activity: 6 new · 12 roles
Priority 8: what the company says
We pursued breakthrough discoveries on three fronts. ... Partnerships were forged to deploy AI to help decode biology, with the potential to accelerate the discovery of new treatmentsEli Lilly and Company 2026 Proxy Statement (DEF 14A), incl. shareholder letter and CD&A, 20 Mar 2026today announced it is building the most powerful supercomputer owned and operated by a pharmaceutical company, in collaboration with NVIDIALilly partners with NVIDIA to build the industry's most powerful AI supercomputer, supercharging medicine discovery and delivery for patients, 28 Oct 2025The supercomputer is the world's first NVIDIA DGX SuperPOD with DGX B300 systems. It is powered by more than 1,000 B300 GPUs on a unified networking fabricLilly partners with NVIDIA to build the industry's most powerful AI supercomputer, 28 Oct 2025Delivery 4, live: what it shows running
Launched a platform, giving biotechnology companies access to artificial intelligence (AI)-enabled drug discovery models.Eli Lilly and Company 2026 Proxy Statement (DEF 14A), incl. shareholder letter and CD&A, 20 Mar 2026Lilly TuneLab, which together support biotech innovation by providing access to strategic capital, lab space and technology, and research and development capabilities including advanced AI models.Lilly announces plans to open Lilly Gateway Labs site in Philadelphia, 19 Nov 2025Lilly TuneLab, an AI and machine learning platform, provides biotech companies with access to select Lilly models for drug discovery built on decades of Lilly's proprietary data.NVIDIA and Lilly Announce Co-Innovation AI Lab to Reinvent Drug Discovery in the Age of AI, 12 Jan 2026Commitments made public in the last 12 months: 6
- Profluent AI-designed recombinase collaboration New, announced, 28 Apr 2026, source: partner only
- Insilico Medicine global R&D collaboration and licence (2026) New, announced, 29 Mar 2026, source: partner release, company quoted
- Lilly AI factory (LillyPod) and NVIDIA AI co-innovation lab Expanded, announced, 12 Jan 2026, source: joint release
- Chai Discovery biologics AI collaboration New, announced, 12 Jan 2026, source: partner only
- BigHat Biosciences antibody design collaboration Expanded, announced, 8 Jan 2026, source: partner only
- Insilico Medicine research and licensing collaboration (from 2023 software licence) Expanded, announced, 10 Nov 2025, source: partner only
Prior 12 months: 6. Search coverage: partial.
R&D roles open on 6 Oct 2026: 12
- Scientific Lead - Forward Deployed AI Engineer, Applied Intelligence for Discovery San Francisco, California, United States of America
- Sr. AI Science Lead South San Francisco, California, United States of America
- AI Scientist (Model Building & Training) South San Francisco, California, United States of America
- HPC Systems Administrator South San Francisco, California, United States of America
- Director / Senior Director - Cheminformatics and Applied AI Boston, Massachusetts, United States of America
- Advisor - Agentic Automation, Frontier AI South San Francisco, California, United States of America
and 6 more in the company brief.
Technology named in these postings
Named as in use: Lilly TuneLab, Hamilton, Tecan, Opentrons, LillyPod (NVIDIA Blackwell Ultra SuperPOD)
Asked for as experience: AWS, PyTorch, NVIDIA GPU infrastructure
Showing up to three quotes for each score. Observed activity is a count of public signals, not a score, and search coverage varies by company. The full account brief for Eli Lilly lists every source.
Novo Nordisklive
Priority 8 / Delivery 4
Observed activity: 4 new · 2 roles
Priority 8: what the company says
Key research & development enablers ... End-to-end AI ... and data scienceCapital Markets Day 2026: R&D strategy (Lange, Patel), 21 Sep 2026, p. 3Significant changes in our R&D set-up ... and AI capabilities to deliver at quality ... and paceCapital Markets Day 2026: R&D strategy (Lange, Patel), 21 Sep 2026, p. 14External innovation is a key enabler to expand the pipeline and strengthen competencies in AI ... Partnering with leading AI providersCapital Markets Day 2026: Corporate strategy presentation, 21 Sep 2026, p. 12Delivery 4, live: what it shows running
AI is leveraged to improve speed, success and productivity across the research & development value chain Select achievements in 2026Capital Markets Day 2026: R&D strategy presentation, 21 Sep 2026, p. 7Pre-clinical asset identified with key outputs ... Combine human-designed sequences with ML-assisted design in an ... active-learning loopCapital Markets Day 2026: R&D strategy (Lange, Patel), 21 Sep 2026, p. 8Novo Nordisk and AWS have created a co-innovation hub in London ... to compress the path from drug target to first human dose ... a dedicated co-innovation hub within our existing facility in LondonNovo Nordisk and AWS enter strategic partnership to accelerate drug discovery through AI, 10 Aug 2026Commitments made public in the last 12 months: 4
- Orbis Medicines AI-enabled macrocycle discovery collaboration and investment New, announced, 17 Sep 2026, source: partner release, company quoted
- Anthropic drug discovery collaboration New, announced, 16 Sep 2026, source: joint release
- AWS strategic AI partnership and London co-innovation hub New, operational, 10 Aug 2026, source: joint release
- OpenAI strategic partnership New, announced, 14 Apr 2026, source: company
Prior 12 months: 6. Search coverage: partial.
R&D roles open on 6 Oct 2026: 2
- Data Science Specialist, Computational Real-World Evidence (cRWE), Data Science, London United Kingdom, London
- PKPD Senior Principal Scientist Denmark, Måløv
Showing up to three quotes for each score. Observed activity is a count of public signals, not a score, and search coverage varies by company. The full account brief for Novo Nordisk lists every source.
AstraZenecascaled
Priority 7 / Delivery 6
Observed activity: 5 new · 6 roles
Priority 7: what the company says
we are investing significantly in transformative technologies that will shape the future of medicine ... This includes harnessing the power of AI where, for example, 90% of our small molecule discovery pipeline is already AI-assistedAstraZeneca Annual Report & Form 20-F Information 2025, 18 Feb 2026, p. 7Our $2.5 billion investment expands early discovery and development and incorporates an AI and data science laboratory.AstraZeneca Annual Report & Form 20-F Information 2025, 18 Feb 2026, p. 7In R&D, we are developing an ecosystem of foundation models and AI agentic frameworks to accelerate our drug discoveryAstraZeneca Annual Report & Form 20-F Information 2025, 18 Feb 2026, p. 38Delivery 6, scaled: what it shows running
Over 90% of our small molecule discovery pipeline is AI-enabled, with similar approaches actively applied to other areas, including biologics.AstraZeneca Annual Report & Form 20-F Information 2025, 18 Feb 2026, p. 38>90% of our small molecule discovery pipeline is enabled by AIAI & data in Drug Discovery & R&D (corporate R&D page), Aug 2026Delivered industry-leading genomic insights while remaining sustainable, redesigning algorithms that cut CO2 emissions and compute time by 99.8% compared to global standards.AstraZeneca Annual Report & Form 20-F Information 2025, 18 Feb 2026, p. 30Commitments made public in the last 12 months: 5
- AISB Bind federated binding-affinity model (AISB Network) New, announced, 22 Sep 2026, source: joint release
- CSPC AI-enabled research collaborations Expanded, announced, 30 Jan 2026, source: company
- LIGAND-AI IHI consortium (open protein-ligand data for AI) New, in build, 20 Jan 2026, source: joint release
- Illumina Billion Cell Atlas founding participation New, in build, 13 Jan 2026, source: partner release, company quoted
- Algen AlgenBrain immunology target discovery partnership New, announced, 6 Oct 2025, source: partner release, company quoted
Prior 12 months: 3. Search coverage: partial.
R&D roles open on 6 Oct 2026: 6
- Associate Director, AI Engineering for Discovery Barcelona, Spain, posting since closed
- Associate Director, AI for Discovery - New Target Discovery Cambridge, Massachusetts, US, posting since closed
- Agentic AI Sr. Engineer Cambridge, MA or Gaithersburg, MD, US
- Computational Biologics Design - Associate Principal Scientist Cambridge, UK
- Associate Director, Translational Data Science - Translational Medicine and Bioinformatics Cambridge, Massachusetts, US
- Associate Director, Digital Proteomics and AI Innovation Gaithersburg, Maryland, US
Technology named in these postings
Named as in use: AWS, Claude Code, Claude Cowork, Confluence, Domino, GitHub, GitHub Copilot, Hugging Face, Kubernetes, M365 Copilot, NVIDIA DGX SuperPOD
Asked for as experience: GitHub Actions
Showing up to three quotes for each score. Observed activity is a count of public signals, not a score, and search coverage varies by company. The full account brief for AstraZeneca lists every source.
Bristol Myers Squibbscaled
Priority 7 / Delivery 6
Observed activity: 6 new · 4 roles
Priority 7: what the company says
Our focus on innovation includes leveraging data and integrating AI across the business to become a more efficient organization and accelerate the delivery of medicines to patients.Bristol Myers Squibb 2026 Proxy Statement, 25 Mar 2026, p. 3all of our small molecule experiments and half of our large molecule experiments are now using an AI model to predict probability of successBristol Myers Squibb 2026 Proxy Statement, 25 Mar 2026, p. 3today announced it will expand its compute infrastructure to deploy an NVIDIA DGX SuperPOD with DGX Vera Rubin NVL72 systemsBristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA, 20 Jul 2026Delivery 6, scaled: what it shows running
builds on nearly three years of collaboration that began when BMS first deployed NVIDIA DGX SuperPOD infrastructure to support its Research and Development activitiesBristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA, 20 Jul 2026all of our small molecule experiments and half of our large molecule experiments are now using an AI model to predict probability of successBristol Myers Squibb 2026 Proxy Statement, 25 Mar 2026, p. 3AI informs the design of every small molecule program and the majority of the company’s large molecule programsBristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA, 20 Jul 2026Commitments made public in the last 12 months: 6
- AISB Bind federated binding-prediction initiative (Apheris) New, announced, 22 Sep 2026, source: partner release, company quoted
- Chai Discovery AI antibody discovery collaboration New, announced, 20 Aug 2026, source: partner only
- Schrödinger Bunsen agentic AI co-scientist deployment New, announced, 5 Aug 2026, source: media only
- NVIDIA DGX SuperPOD AI factory for R&D (with Equinix-hosted infrastructure) Expanded, announced, 20 Jul 2026, source: company
- insitro ALS discovery collaboration Expanded, announced, 14 Oct 2025, source: joint release
- Orbital Therapeutics acquisition (RNA platform with AI-driven design) New, announced, 10 Oct 2025, source: joint release
Prior 12 months: 3. Search coverage: partial.
R&D roles open on 6 Oct 2026: 4
- Associate Director - Machine Learning Sciences Cambridge Crossing - MA - US
- Principal Research AI Innovation Lead Remote - United States - US
- Principal Scientist - Computational Sciences San Diego - CA - US
- Principal Scientist, Computational Biology Cambridge Crossing - MA - US
Showing up to three quotes for each score. Observed activity is a count of public signals, not a score, and search coverage varies by company. The full account brief for Bristol Myers Squibb lists every source.
Daiichi Sankyolive
Priority 7 / Delivery 4
Observed activity: 1 new · 1 role
Priority 7: what the company says
Identify next BGTs by 2030 ... 当社は、2030年までに次世代のBGTsを特定することを重要な戦略目標として位置づけております。 ... 国内外の研究拠点の拡充やAI・データ駆動型創薬の推進[Ortent translation: We have set identifying next-generation BGTs by 2030 as an important strategic goal. ... expanding our research sites in Japan and overseas and advancing AI and data-driven drug discovery]
有価証券報告書 第21期 (Annual Securities Report FY2025, 1 Apr 2025-31 Mar 2026), 19 Jun 2026, p. 12Expanding Drug Discovery Research Capabilities: ... Expanding and strategizing AI-driven drug discovery into multi-modality research ... AI-driven molecular designFY2025 Financial Results and 5-Year Business Plan Presentation & Discussion (FY2026-FY2030), 11 May 2026, p. 69Smart Lab: Enabling Competitive AI-driven Drug Discovery ... Seamless data feedback to molecular design AI ... Smart Lab is the cornerstone of AI-driven drug design success.Science & Technology Day 2025, 16 Dec 2025, p. 85Delivery 4, live: what it shows running
OpenFold-3をはじめとする最先端のAIモデルを社内環境に導入し、研究者が利用できるアプリケーションとしてクラウド環境上で提供しています。[Ortent translation: We have brought state-of-the-art AI models, starting with OpenFold-3, into our internal environment and provide them in the cloud as applications our researchers can use.]
DX - データと先進デジタル技術の活用 (DX corporate page), No printed date. Its content dates it to Jul 2026 or later, and we read it on 6 Oct 2026大規模言語モデルによるヒト遺伝子データの分析 複雑で膨大な遺伝子情報を高性能Graphics Processing Unit(GPU)で処理し[Ortent translation: Analysis of human genetic data with large language models. Complex and vast genetic information is processed on high-performance graphics processing units (GPUs) and]
DXを継続的に動かす基盤と体制 (DX enablers page), No printed date. Its content dates it to May 2026 or later, and we read it on 6 Oct 2026AIエージェントをバイオインフォマティクス業務に導入し、生命科学データの探索・解析を効率化・高度化しています。実際のデータ解析業務を通じてその有用性を検証し[Ortent translation: We have introduced AI agents into bioinformatics work, making the exploration and analysis of life science data more efficient and more advanced. We are testing their usefulness through real data analysis work and]
DX - データと先進デジタル技術の活用 (DX corporate page), No printed date. Its content dates it to Jul 2026 or later, and we read it on 6 Oct 2026Commitments made public in the last 12 months: 1
- Turbine vLab virtual assays for ADC discovery Expanded, announced, 24 Sep 2026, source: partner only
Prior 12 months: 2. Search coverage: partial.
R&D roles open on 6 Oct 2026: 1
- Biomodality design, senior scientist DSHQ バイオモダリティデザイン(Senior Scientist), Tokyo, Japan (Shinagawa)
Showing up to three quotes for each score. Observed activity is a count of public signals, not a score, and search coverage varies by company. The full account brief for Daiichi Sankyo lists every source.
Regeneronlive
Priority 7 / Delivery 4
Observed activity: 0 new · 3 roles
Priority 7: what the company says
We aim to complete sequencing of 10 million samples and integrate AI and big data tools to improve drug discovery and digital health solutions by 2030.2025 Responsibility Report, 28 Apr 2026, p. 17through the Regeneron Genetics Center ... we’re committing to sequencing 10 million samples and integrating artificial intelligence (AI) and big data tools to advance drug discoveryResponsibility at Regeneron: A Look Back and a Look Ahead (story), 28 Apr 2026SCIENCE-LED 2030 GOALS WILL HOLD US ACCOUNTABLE ... Completing sequencing of 10M samples and integrating AI and big data tools to improve drug discoveryRegeneron Corporate Presentation, July 2026, Jul 2026, p. 31Delivery 4, live: what it shows running
We use innovative technologies, such as machine learning, to sequence exomes, align with health information and perform large-scale analyses to make meaningful associations between genes and diseases.Regeneron Collaborates with TriNetX to Access De-identified Electronic Health Records of 300 Million Patients, 2 Apr 2026Our lab technicians, data scientists and bioinformaticians collect and analyze large amounts of data using cloud technology to simultaneously look at genes, proteins, health records and more.The Regeneron Scientific Journey (story), 9 Jun 2026RGC leverages organoid models, siRNA, and CRISPR knockout models to validate genetic associations that lead to new therapeutic targets. ... These efforts at RGC have led to the identification of more than 40 novel genetic targets.Regeneron 2025 Annual Report incl. Form 10-K FY2025, 4 Feb 2026, p. 22Commitments made public in the last 12 months: 0
None identified in the reviewed sources.
Prior 12 months: 0. Search coverage: partial.
R&D roles open on 6 Oct 2026: 3
- Associate Director, Translational PK/PD Modeling TARRYTOWN
- Associate Manager, Statistical Genetics (Applied Bioinformatics Scientist) TARRYTOWN
- Principal Scientist, Translational PK/PD Modeling TARRYTOWN
Technology named in these postings
Asked for as experience: Claude
Showing up to three quotes for each score. Observed activity is a count of public signals, not a score, and search coverage varies by company. The full account brief for Regeneron lists every source.
Astellaslive
Priority 6 / Delivery 7
Observed activity: 1 new · 2 roles
Priority 6: what the company says
A key partnership is our participation in Tokyo-1 ... This initiative utilizes the Tokyo-1 GPU supercomputer to accelerate our research in molecular simulation and AI-based molecular designIntegrated Report 2025 (FY2024, English), 31 Oct 2025, p. 62in drug discovery research, we aim to accelerate the development of biopharmaceuticals and improve productivity, not only through NVIDIA's AI-powered supercomputing for small molecule drug design that has already been implementedAstellas R&D Day event transcript, 31 March 2026, 31 Mar 2026, p. 19Strategic investments in AI will help us improve speed, quality and ... decision-making across R&D ... Research ... Human-in-the-Loop platform, an AI ... and robotics integrated system to optimize drug candidates ... NVIDIA-powered supercomputing to ... dramatically accelerate early-stage ... drug discoveryAstellas R&D Day presentation, 31 March 2026, 31 Mar 2026, p. 21Delivery 7, live: what it shows running
It also includes automated synthesis and assay systems using robots, and tools ... for automatically creating structure-activity relationship (SAR) tables ... The platform also ... incorporates the ability to remotely monitor the operation of the robotsIntegrated Report 2025 (FY2024, English), 31 Oct 2025, p. 61Astellas has been ahead of the curve, integrating AI into its drug development processes since 2019. The company's innovative "Human-in-the-Loop" platform is central to this effortIntegrated Report 2025 (English), 31 Oct 2025, p. 61in drug discovery research, we aim to accelerate the development of biopharmaceuticals and improve productivity, not only through NVIDIA's AI-powered supercomputing for small molecule drug design that has already been implementedAstellas R&D Day event transcript, 31 March 2026, 31 Mar 2026, p. 19Commitments made public in the last 12 months: 1
- AI-enabled Protein Station for biologics discovery automation New, announced, 31 Mar 2026, source: company
Prior 12 months: 0. Search coverage: partial.
R&D roles open on 6 Oct 2026: 2
- Computational Chemistry Lead Cambridge, MA, USA
- Scientist II, Antibody Engineering CA, South San Francisco
Showing up to three quotes for each score. Observed activity is a count of public signals, not a score, and search coverage varies by company. The full account brief for Astellas lists every source.
Sanofiscaled
Priority 6 / Delivery 6
Observed activity: 6 new · 3 roles
Priority 6: what the company says
3) Accelerate efficiency ... AI and data science are already supporting our teams in areas such as accelerating drug discoverySanofi Annual Report on Form 20-F 2025, 17 Feb 2026, p. 28organized around four key priorities: 1) focus on growth; 2) lead with innovation; 3) accelerate efficiency; and 4) reinvent how we workSanofi Annual Report on Form 20-F 2025, 17 Feb 2026, p. 27We are an R&D driven, AI-powered biopharma company committed to improving people’s lives and creating compelling growth.Sanofi Annual Report on Form 20-F 2025, 17 Feb 2026, p. 26Delivery 6, scaled: what it shows running
Digital ... In R&D: ... 90% targets in the pipeline now being credentialed using our data and AI systemsSanofi Annual Report on Form 20-F 2025, 17 Feb 2026, p. 137100% small and large molecule drug design efforts now supported by AI/ML methods, doubling molecular throughput of research teamsSanofi Annual Report on Form 20-F 2025, 17 Feb 2026, p. 137our Target Discovery engines have delivered seven novel drug targets in just one yearSanofi Annual Report on Form 20-F 2025, 17 Feb 2026, p. 28Commitments made public in the last 12 months: 6
- Aqemia physics-based generative AI research collaboration (Dec 2023 onwards) Expanded, in build, 17 Jul 2026, source: partner only
- Computational and AI Strategy, R&D (CompAI) function New, operational, 29 Jun 2026, source: company
- Owkin partnership (2021 onwards), incl. K Pro agentic AI collaboration Expanded, announced, 5 Jun 2026, source: partner release, company quoted
- Sanofi Ventures investment in QuantX Biosciences New, announced, 9 Feb 2026, source: partner only
- Sanofi Ventures investment in Diagonal Therapeutics New, announced, 8 Jan 2026, source: partner release, company quoted
- Earendil Labs discovery collaboration on bispecific antibodies New, announced, 5 Jan 2026, source: partner only
Prior 12 months: 4. Search coverage: partial.
R&D roles open on 6 Oct 2026: 3
- Associate Director - QSP Quantitative Systems Pharmacology Morristown, United States of America
- Associate Director - QSP Quantitative Systems Pharmacology Morristown, United States of America
- Head of Agentic Biology Cambridge (U.S.), United States of America
Showing up to three quotes for each score. Observed activity is a count of public signals, not a score, and search coverage varies by company. The full account brief for Sanofi lists every source.
Amgenlive
Priority 6 / Delivery 4
Observed activity: 2 new · 21 roles
Priority 6: what the company says
Putting AI at the Heart of Drug Discovery ... Amgen is working toward using artificial intelligence and machine learning to shorten that timeline and raise the odds of success.Amgen 2025 Annual Report: Letter to Shareholders and Form 10-K, 18 Mar 2026, p. 4making the following changes effective June 1, 2026 ... will serve as executive vice president, Research and Development, Artificial Intelligence and Data.Amgen Announces Retirement of David M. Reese, EVP and Chief Technology Officer (organizational changes), 22 Apr 2026highlights the company's continued investment in scientific research, artificial intelligence in drug discovery, and advanced manufacturing.Amgen Ranks #4 on Forbes' Most Innovative Large Companies List, 22 Sep 2026Delivery 4, live: what it shows running
Amgen has developed an integrated ... generative loop, where AI and automation continuously refine each other.Bio Meets Tech: How Amgen is Designing the Medicines of Tomorrow, 2 Dec 2025Amgen's AI platforms help identify genetically validated targets, generate novel proteins and predict how drug candidates will perform before they reach the lab.Amgen 2025 Annual Report: Letter to Shareholders and Form 10-K, 18 Mar 2026, p. 4Head's team applies protein and chemistry language models and other AI-enabled design approaches to drug discoveryAmgen's Approach to AI-Enabled Clinical Development, 20 May 2026Commitments made public in the last 12 months: 2
- South San Francisco small-molecule discovery labs ($125M) New, operational, 6 May 2026, source: company
- EVP Research and Development, Artificial Intelligence and Data (April 2026 organisation change) New, announced, 22 Apr 2026, source: company
Prior 12 months: 0. Search coverage: partial.
R&D roles open on 6 Oct 2026: 21
- Sr Associate Data Scientist Hyderabad, India
- Agentic AI Lead - Protein Design & Molecular Engineering Hyderabad, India
- Agentic AI Lead - Disease Biology & Target Discovery Hyderabad, India, posting since closed
- Principal Scientist - AI/ML Workflow & Ecosystem Lead (Large Molecule Discovery Informatics) Hyderabad, India
- Associate Scientist - Digital Discovery: Antibody Bioinformatics Burnaby, British Columbia, Canada
- Senior Scientist - Computational Protein Design South San Francisco, California, United States of America
and 15 more in the company brief.
Technology named in these postings
Asked for as experience: Docker, AWS, Hugging Face, Databricks, MLflow, Kubernetes
Showing up to three quotes for each score. Observed activity is a count of public signals, not a score, and search coverage varies by company. The full account brief for Amgen lists every source.
BayerProvisional
Priority 6 / Delivery 4
Observed activity: 3 new · 5 roles
Priority 6: what the company says
"Our ambition is to leverage AI to increase R&D productivity by 40 percent by 2030," said Sai Jasti, Senior Vice President, Head of Data Science & Artificial Intelligence, Bayer Pharmaceuticals R&D.Bayer's strongest-ever pharma portfolio and promising pipeline drive future growth (Pharma Media Day 2026, News Release 2026-0056e), 1 Apr 2026, p. 12By integrating AI platform architecture with anonymized ... data, our data scientists are empowered to maximize our in-house biologics portfolio, validate AI models, and scale solutions, thereby ultimately speeding up drug discovery.Bayer's strongest-ever pharma portfolio and promising pipeline drive future growth (Pharma Media Day 2026, News Release 2026-0056e), 1 Apr 2026, p. 12Through this acquisition, Bayer subsidiary Vividion Therapeutics Inc. is expanding its capabilities in terms of proprietary methods for computer-based genomic screening. ... Bayer paid an upfront consideration of around €19 million to acquire Tavros.Bayer Annual Report 2025 (entire report PDF), 4 Mar 2026, p. 294Delivery 4, live: what it shows running
Combining the Tavros platform with Vividion’s chemoproteomics expertise and capabilities continues to greatly enhance Vividion’s efforts to generate potential best- and first-in-class drug targets across oncology and immunology.Bayer Annual Report 2025 (entire report PDF), 4 Mar 2026, p. 47Following a successful proof of concept, Bayer selected Cradle as its best suited partner from among several vendors.Bayer and Cradle enter collaboration to enhance AI-enabled antibody discovery and optimization (News Release 2026-0009e), 7 Jan 2026, p. 2entered a three-year strategic collaboration to deploy Cradle's scientific AI software platform for protein engineering ... Bayer will integrate the generative AI platform into existing R&D workflows to enhance lead generation and optimization across its therapeutic antibody pipeline.Bayer and Cradle enter collaboration to enhance AI-enabled antibody discovery and optimization (News Release 2026-0009e), 7 Jan 2026, p. 1Commitments made public in the last 12 months: 3
- Iambic AI small-molecule discovery collaboration New, announced, 22 Jun 2026, source: joint release
- Vanderbilt University Medical Center discovery collaboration (BioVU data) New, announced, 20 Jan 2026, source: joint release
- Cradle AI protein engineering platform collaboration (antibodies) New, announced, 7 Jan 2026, source: joint release
Prior 12 months: 1. Search coverage: partial.
R&D roles open on 6 Oct 2026: 5
- Head of Machine Learning Research Whippany,New Jersey,United States
- Head of Machine Learning Research (all genders) Berlin,Berlin,Germany
- Senior Principal Scientist (all genders) - Quantum Mechanics and Modeling Wuppertal-Aprath,North Rhine Westfalia,Germany
- Principal Machine Learning Scientist (all genders) Berlin,Berlin,Germany
- Principal Machine Learning Scientist (all genders) Wuppertal-Aprath,North Rhine Westfalia,Germany
Provisional: a published company document could not be read in full, so these scores may change. Showing up to three quotes for each score. Observed activity is a count of public signals, not a score, and search coverage varies by company. The full account brief for Bayer lists every source.
GSKlive
Priority 6 / Delivery 4
Observed activity: 3 new · 2 roles
Priority 6: what the company says
At every step of the R&D process, we are using data tech, including AI, and platform technologies to be faster, more effective and more predictive in discovering and developing innovative medicines and vaccines.GSK Annual Report 2025, 5 Mar 2026, p. 5Our AI-powered, end-to-end oligonucleotide platform, 'Oligopolis', which incorporates the Elsie platform we acquired in 2024, is redefining research in chemistry and biology. The platform automates cycles of design, synthesis and testingGSK Annual Report 2025, 5 Mar 2026, p. 34GSK announced that it had acquired Elsie Biotechnologies, a San Diego-based private biotechnology company dedicated to unlocking the full potential of oligonucleotide therapeutics, for a total consideration of up to US$51 millionGSK Annual Report 2025, 5 Mar 2026, p. 245Delivery 4, live: what it shows running
Our digital chemistry platform uses AI/machine learning (ML) and automation to accelerate design-build-test cycles in small-molecule discovery.GSK Annual Report 2025, 5 Mar 2026, p. 34Our AI-powered, end-to-end oligonucleotide platform, 'Oligopolis', which incorporates the Elsie platform we acquired in 2024, is redefining research in chemistry and biology. The platform automates cycles of design, synthesis and testingGSK Annual Report 2025, 5 Mar 2026, p. 34GSK uses these AI methods to compare expression data from healthy lung tissue with samples from COPD patientsMapping disease at the cellular level: A single-cell revolution in drug discovery (Behind the Science), 12 Dec 2025Commitments made public in the last 12 months: 3
- Relation Therapeutics target-discovery collaborations Expanded, announced, 30 Jul 2026, source: partner only
- Noetik OCTO-VC foundation model licence New, announced, 8 Jan 2026, source: partner release, company quoted
- GSK-Teichmann Laboratory single-cell collaboration New, operational, 12 Dec 2025, source: company
Prior 12 months: 2. Search coverage: partial.
R&D roles open on 6 Oct 2026: 2
- ViiV Healthcare (GSK) Scientific Leader, Pre-clinical DMPK Drug Discovery Modeling Branford, Connecticut, United States of America
- Associate Director, QSP Modelling Collegeville, Pennsylvania, United States of America
Showing up to three quotes for each score. Observed activity is a count of public signals, not a score, and search coverage varies by company. The full account brief for GSK lists every source.
Merck KGaAlive
Priority 6 / Delivery 4
Observed activity: 1 new · 3 roles
Priority 6: what the company says
we also use it internally in our Healthcare business sector in early stages of drug discovery. Our AI in drug discovery program will accelerate the discovery of new and better drug candidates2025 Annual Report of Merck KGaA, Darmstadt, Germany (2025-Q4-Report-NA.pdf), 5 Mar 2026, p. 41successfully launch a state-of-the-art high-performance computer in Munich, Germany, designed to accelerate innovation across the three business sectors ... streamline drug discovery processes in its Healthcare business sectorone-HPC: High-performance computer launched with Lenovo and Equinix, 20 Nov 2025RDKit helps our research and development scientists within our Healthcare business sector ... said Arvind Rajpal, Head of Discovery & Development Technologies at Research and Development within the Healthcare business sector of Merck KGaA, Darmstadt, GermanyRDKit conference with more than 300 participants (news release), 21 Sep 2026Delivery 4, live: what it shows running
AIDDISON™, our generative AI-powered active ingredient discovery platform. In addition to external commercialization, we also use it internally in our Healthcare business sector in early stages of drug discovery.2025 Annual Report of Merck KGaA, Darmstadt, Germany (2025-Q4-Report-NA.pdf), 5 Mar 2026, p. 41Predictive Modeling Platform , a tool for AI-driven design of drug-like molecules for the Healthcare business sector, recently recognized with an in-house awardRDKit conference with more than 300 participants (news release), 21 Sep 2026RDKit helps our research and development scientists within our Healthcare business sector turn chemical data into AI-ready representations and actionable insights for faster, better-informed molecular design.RDKit conference with more than 300 participants (news release), 21 Sep 2026Commitments made public in the last 12 months: 1
- Group high-performance computer (Lenovo, Equinix) New, operational, 20 Nov 2025, source: company
Prior 12 months: 1. Search coverage: partial.
R&D roles open on 6 Oct 2026: 3
- Senior Scientist - Oligo Bioinformatics Billerica, Massachusetts, United States
- Principal Scientist, Synthetic & Discovery Chemistry Billerica, Massachusetts, United States
- Principal Scientist, Translational Quantitative Pharmacology Billerica, Massachusetts, United States
Showing up to three quotes for each score. Observed activity is a count of public signals, not a score, and search coverage varies by company. The full account brief for Merck KGaA lists every source.
Johnson & Johnsonlive
Priority 5 / Delivery 4
Observed activity: 4 new · 10 roles
Priority 5: what the company says
says Justin Scheer, Vice President, In Silico Discovery, Innovative Medicine R&D, Johnson & Johnson ... Using our highly sophisticated AI, built on in-house data, we aim to accelerate the delivery of medicines6 ways Johnson & Johnson is using AI to help advance healthcare, 8 Apr 2026Once promising disease targets are identified, Johnson & Johnson is then leveraging AI to help discover molecules that could interact with the target.6 ways Johnson & Johnson is using AI to help advance healthcare, 8 Apr 2026By combining data, AI and machine learning (ML), and advanced computing with our scientific expertise, Johnson & Johnson is setting a new pace for discovering life-changing treatments for patients in need.Artificial Intelligence - advancing healthcare from New Jersey to the world, 4 Sep 2026Delivery 4, live: what it shows running
Johnson & Johnson is then leveraging AI to help discover molecules that could interact with the target. ... The company is doing this through its own state-of-the-art technologies, as well as in partnership with external collaborators.6 ways Johnson & Johnson is using AI to help advance healthcare, 8 Apr 2026So in molecular design in discovery, it's shortening the time from hit to lead. So we can do things faster.Johnson & Johnson at Bernstein Strategic Decisions Conference (transcript), 27 May 2026, p. 7So we have a number of examples of oral medicines that we are getting into humans much faster than we were able to do pre utilizing AI. ... we are clearly using it, and it's already ongoing.Johnson & Johnson at Bernstein Strategic Decisions Conference (transcript), 27 May 2026, p. 8Commitments made public in the last 12 months: 4
- AISB Network AISB Bind federated binding-affinity initiative New, announced, 22 Sep 2026, source: joint release
- Isomorphic Labs cross-modality research collaboration New, announced, 20 Jan 2026, source: partner only
- Data & AI Fueling R&D of Tomorrow QuickFire Challenge (Singapore & Beyond) New, announced, 20 Nov 2025, source: company
- CAT-PD QuickFire Challenge (computational de novo antibody design) New, announced, 8 Oct 2025, source: company
Prior 12 months: 2. Search coverage: partial.
R&D roles open on 6 Oct 2026: 10
- Senior Principal Scientist, Preclinical Safety & Translational Sciences-Translational Pharmacokinetics/Pharmacodynamics San Diego, California, United States of America, Spring House, Pennsylvania, United States of America
- Principal Scientist, AI & Autonomous Discovery Systems - Spring House, PA Spring House, Pennsylvania, United States of America
- Senior Data Scientist, Biologics Discovery Madrid, Spain, Raritan, New Jersey, United States of America, Spring House, Pennsylvania, United States of America, Titusville, New Jersey, United States of America
- Principal Agentic Workflow & AI Engineer, Biologics Discovery Raritan, New Jersey, United States of America, Spring House, Pennsylvania, United States of America, Titusville, New Jersey, United States of America
- Senior Data Scientist, Biologics Discovery - Madrid, ES Madrid, Spain
- Senior Machine Learning Engineer, Biologics Discovery Beerse, Antwerp, Belgium, Madrid, Spain, Raritan, New Jersey, United States of America, Spring House, Pennsylvania, United States of America, Titusville, New Jersey, United States of America
and 4 more in the company brief.
Showing up to three quotes for each score. Observed activity is a count of public signals, not a score, and search coverage varies by company. The full account brief for Johnson & Johnson lists every source.
MSDlive
Priority 5 / Delivery 4
Observed activity: 4 new · 3 roles
Priority 5: what the company says
The collaboration builds on Merck's broader investments in AI/ML-enabled discovery, spanning computational or spatial biology, AI foundation models and real-world dataMerck and Mayo Clinic Announce New Research and Development Collaboration to Support AI-Enabled Drug Discovery and Precision Medicine, 18 Feb 2026Merck's ambition to harness AI-enabled virtual cell technologies to enhance disease understanding, improve target identification and drive early development decisionsMerck and Mayo Clinic Announce New Research and Development Collaboration to Support AI-Enabled Drug Discovery and Precision Medicine, 18 Feb 2026We also use data science, AI, and machine learning ... (ML) to help overcome bottlenecks in discovery, research, and development.Purpose for Progress Impact Report 2025/2026, 18 Aug 2026, p. 22Delivery 4, live: what it shows running
KERMT isn't just helping our researchers; as an open-source model, its code is available to the whole scientific community.Our AI model KERMT is helping to advance drug discovery (story), 19 Mar 2026We recently developed two foundation models which uncover patterns in disease to find better drug targets, allow faster molecular design and rapidly test small molecules5 ways we're transforming artificial intelligence into impact (story), 9 Jan 2026Developed in collaboration with Nvidia, KERMT, pronounced "Kermit" and short for Kinetic GROVER Multi-Task, is a deep-learning computer model trained on more than 11 million molecules.Our AI model KERMT is helping to advance drug discovery (story), 19 Mar 2026Commitments made public in the last 12 months: 4
- Protillion lab-in-the-loop AI protein design collaboration New, announced, 16 Jun 2026, source: partner release, company quoted
- Infinimmune antibody discovery collaboration New, announced, 31 Mar 2026, source: partner release, company quoted
- Mayo Clinic Platform_Orchestrate AI R&D collaboration New, announced, 18 Feb 2026, source: joint release
- Illumina Billion Cell Atlas alliance (founding participant) New, in build, 13 Jan 2026, source: partner release, company quoted
Prior 12 months: 2. Search coverage: partial.
R&D roles open on 6 Oct 2026: 3
- Associate Director, AI/ML Engineering Cambridge, Massachusetts, United States of America | B (Workday): USA - Massachusetts - Cambridge (320 Bent Street)
- Sr. Manager, MCICC - AI Shanghai, Shanghai, China
- Senior Specialist, Data Analysis Cambridge, Massachusetts, United States of America | B (Workday): USA - Massachusetts - Cambridge (320 Bent Street)
Technology named in these postings
Asked for as experience: Amazon Web Services (AWS), Claude Code, Databricks, Docker, GitHub Actions, Google Cloud Platform (GCP), MLflow, Python, PyTorch
Showing up to three quotes for each score. Observed activity is a count of public signals, not a score, and search coverage varies by company. The full account brief for MSD lists every source.
Modernalive
Priority 5 / Delivery 4
Observed activity: 1 new · 4 roles
Priority 5: what the company says
Power innovation through our Scientific Intelligence Engine Harness data, AI/ML, automation, and robotics to accelerate discovery and continuously improve how we workModerna Science Day 2026 presentation, 25 Jun 2026, p. 116Our AI strategy turns platform data and biological insight into faster innovationModerna Science Day 2026 presentation, 25 Jun 2026, p. 10Across Moderna, we are building what we call our Scientific Intelligence Engine—a system that combines data, AI and machine learning, automation, and robotics to accelerate discovery and improve how we work.Building Moderna's Next Decade of Growth (Stephane Bancel, Science Day post), 25 Jun 2026Delivery 4, live: what it shows running
At the research stage, our digital and AI infrastructure allows our scientists to design novel mRNA constructs, use AI algorithms to optimize them and order them from our high throughput preclinical scale production line.Moderna Form 10-K for fiscal year ended 31 December 2025, 20 Feb 2026, p. 26Lucy is at the heart of Moderna's scientific intelligence engine. Lucy connects everything that we've built in AI, automation, experimentation, and data into a continuously improving learning system.Moderna Science Day transcript (LSEG StreetEvents), 25 Jun 2026, p. 25We do have an ongoing program to try and improve this algorithm. In fact, we're using artificial intelligence to try to develop the next algorithm.Q2 2026 Moderna earnings call transcript, 31 Jul 2026, p. 9Commitments made public in the last 12 months: 1
- University of Alberta AI model for mRNA structure and translation New, announced, 6 Jan 2026, source: partner only
Prior 12 months: 0. Search coverage: partial.
R&D roles open on 6 Oct 2026: 4
- Principal Scientist, Protein Design Cambridge, Massachusetts (325 Binney St - Cambridge - USA - MA)
- Sr. Scientist, Protein Design Cambridge, Massachusetts (325 Binney St - Cambridge - USA - MA)
- Sr. Scientist, Therapeutics & Translational Bioinformatics Cambridge, Massachusetts (325 Binney St - Cambridge - USA - MA)
- Sr. Research Associate, Protein Design Cambridge, Massachusetts (325 Binney St - Cambridge - USA - MA)
Showing up to three quotes for each score. Observed activity is a count of public signals, not a score, and search coverage varies by company. The full account brief for Moderna lists every source.
UCBlive
Priority 5 / Delivery 4
Observed activity: 3 new · 1 role
Priority 5: what the company says
UCB has acquired the Patient Insight Business of IMIDomics ... which applies advanced biostatistics, machine learning, and AI to uncover new therapeutic targets, responder biomarkersUCB announces acquisition of IMIDomics' Patient Insight Business, 1 May 2026Patient Insight Business enhances UCB’s ability to identify novel drug targets, discover responder biomarkers, and design molecularly informed patient stratification approachesUCB announces acquisition of IMIDomics' Patient Insight Business, 1 May 2026On 1 May 2026, the Group acquired the Patient Insight Business of IMIDomics. The acquisition provides UCB with direct access to one of the most advanced, deeply curated human datasets in immunologyUCB 2026 Half-Year Financial Report, 30 Jul 2026, p. 29Delivery 4, live: what it shows running
Our collaborations with Schrödinger are also integrating advanced modeling and computational design, to accelerate discovery and enhance data quality across key R&D pillars such as multi-specific medicines and digital antibody engineering.UCB Integrated Annual Report 2025, 26 Feb 2026, p. 19On 1 May 2026, the Group acquired the Patient Insight Business of IMIDomics. The acquisition provides UCB with direct access to one of the most advanced, deeply curated human datasets in immunologyUCB 2026 Half-Year Financial Report, 30 Jul 2026, p. 29In January 2025, UCB entered into a license agreement on XtalFold™, a biologics AI platform developed by Ailux Biologics, a division of XtalPi. UCB will leverage XtalFold™ for the discovery and engineering of biologics.UCB Integrated Annual Report 2025, Feb 2026, p. 180Commitments made public in the last 12 months: 3
- Barcelona R&D Hub and in-house AI precision medicine platform New, in build, 22 Sep 2026, source: company
- IMIDomics: equity investment and acquisition of the Patient Insight Business New, announced, 1 May 2026, source: joint release
- DARC: Digital Antibody Research Collaboration with the University of Southampton New, announced, 27 Apr 2026, source: joint release
Prior 12 months: 1. Search coverage: partial.
R&D roles open on 6 Oct 2026: 1
- Lead Full-Stack AI Product Engineer - Barcelona (SP) N/A, N/A, Spain
Technology named in these postings
Asked for as experience: Python, R
Showing up to three quotes for each score. Observed activity is a count of public signals, not a score, and search coverage varies by company. The full account brief for UCB lists every source.
Boehringer Ingelheimbuild underway
Priority 5 / Delivery 3
Observed activity: 8 new · 11 roles
Priority 5: what the company says
Anticipated £150M investment over 10 years as part of Boehringer's commitments in AI across R&D, with the first 50 AI experts in place by end of 2027Boehringer Ingelheim expands investment in computational innovation with new AI Accelerator in UK Knowledge Quarter, 20 Apr 2026Computational science is central to our innovation strategy.Computational Innovation (UK corporate page), 7 Apr 2026Computational Innovation identifies and builds confidence in new therapeutic concepts and increases the likelihood of success across our portfolio.Partnering in Computational Innovation flyer (June 2026), 18 Jun 2026, p. 1Delivery 3, build underway: what it shows running
Boehringer Ingelheim today announced the expansion of its global Computational Innovation footprint with the launch of a new center for AI and machine learning in King's Cross, London, UKBoehringer Ingelheim expands investment in computational innovation with new AI Accelerator in UK Knowledge Quarter, 20 Apr 2026Computational Innovation now has locations in Austria, Germany, UK and USA specializing in AI, machine learning, human genetics, and computational biology.Boehringer Ingelheim expands investment in computational innovation with new AI Accelerator in UK Knowledge Quarter, 20 Apr 2026Molecule design: Leveraging AI to help create high-quality molecules faster.Computational Innovation (UK corporate page), 7 Apr 2026Commitments made public in the last 12 months: 8
- Variant Bio AI genomics target discovery collaboration Expanded, announced, 23 Sep 2026, source: partner release, company quoted
- Envisagenics SpliceCore target collaboration New, announced, 22 Sep 2026, source: partner release, company quoted
- Owkin K Pro AI Scientist and data licence New, announced, 2 Sep 2026, source: partner only
- Immunai single-cell AI T-cell target collaboration New, announced, 25 Jun 2026, source: partner release, company quoted
- London AI Accelerator (Computational Innovation UK) New, in build, 20 Apr 2026, source: company
- OpenProtein.AI antibody design platform Expanded, announced, 31 Mar 2026, source: partner only
- Galux AI protein design research agreement New, announced, 17 Dec 2025, source: partner only
- MOLCURE AI antibody discovery research agreement New, announced, 7 Oct 2025, source: partner only
Prior 12 months: 1. Search coverage: partial.
R&D roles open on 6 Oct 2026: 11
- AI Accelerator for Drug Discovery - Talent Pool London, UK
- ML Engineer London, UK
- Senior ML Engineer London, UK
- Senior Staff MLOps Engineer London, UK
- Senior Staff AI Infrastructure Engineer London, UK
- Senior Data Engineer London, UK
and 5 more in the company brief.
Technology named in these postings
Asked for as experience: Python
Showing up to three quotes for each score. Observed activity is a count of public signals, not a score, and search coverage varies by company. The full account brief for Boehringer Ingelheim lists every source.
AbbViefunded or contracted
Priority 5 / Delivery 2
Observed activity: 3 new · 6 roles
Priority 5: what the company says
Through our areas of innovation, which include data convergence, artificial intelligence (AI), genetic medicine and genomics, patient-focused disease medicine and therapeutic modalities, we are leveraging powerful tools in order to accelerate discoveryAbbVie 2025 ESG Action Report, No printed date. Its content dates it to 23 Mar 2026 or later, and we read it on 6 Oct 2026, p. 17AI: We are integrating AI into our R&D processes to support improved drug discovery and development. We use AI to extract knowledge from data across our entire pipeline, from enabling more efficient molecule property predictionAbbVie 2025 ESG Action Report, No printed date. Its content dates it to 23 Mar 2026 or later, and we read it on 6 Oct 2026, p. 18Under the terms of the collaboration, Iambic will receive an upfront payment and is eligible to receive success-based milestone payments and tiered royalties on net sales from products generated from the collaboration.AbbVie and Iambic Announce Collaboration to Accelerate AI-driven Drug Discovery, 21 Sep 2026Delivery 2, funded or contracted: what it shows running
today announced a multi-year collaboration to accelerate the discovery and development of small molecule therapies with first-in-class and best-in-class potential across immunology, neuroscience and oncologyAbbVie and Iambic Announce Collaboration to Accelerate AI-driven Drug Discovery, 21 Sep 2026Under the terms of the collaboration, Iambic will receive an upfront payment and is eligible to receive success-based milestone payments and tiered royalties on net sales from products generated from the collaboration.AbbVie and Iambic Announce Collaboration to Accelerate AI-driven Drug Discovery, 21 Sep 2026AI: We are integrating AI into our R&D processes to support improved drug discovery and development. We use AI to extract knowledge from data across our entire pipeline, from enabling more efficient molecule property predictionAbbVie 2025 ESG Action Report, No printed date. Its content dates it to 23 Mar 2026 or later, and we read it on 6 Oct 2026, p. 18Commitments made public in the last 12 months: 3
- Antibody Developability Consortium (Ginkgo Datapoints and Apheris) New, announced, 29 Sep 2026, source: partner release, company quoted
- AISB Network: AISB Bind binding-prediction initiative (Apheris) New, announced, 22 Sep 2026, source: partner release, company quoted
- Iambic AI-driven small-molecule discovery collaboration New, announced, 21 Sep 2026, source: joint release
Prior 12 months: 2. Search coverage: partial.
R&D roles open on 6 Oct 2026: 6
- Director, Computational HitGen / LeadGen Team Lead North Chicago, IL
- Director, Computational Sciences North Chicago, IL
- Principal Research Scientist II, Computational Sciences, MPDD North Chicago, IL
- China AI/ML, Automation, and Capability Expansion Lead, Biotherapeutics and Genetic Medicine Shanghai, Shanghai
- Senior Scientist I - II, Computational HitGen / LeadGen North Chicago, IL
- Principal Data Architect II, Biotherapeutics and Genetic Medicine Worcester, MA
Technology named in these postings
Named as in use: ARCH (AbbVie R&D Convergence Hub)
Showing up to three quotes for each score. Observed activity is a count of public signals, not a score, and search coverage varies by company. The full account brief for AbbVie lists every source.
Novartisclaimed
Priority 5 / Delivery claimed
Observed activity: 3 new · 8 roles
Priority 5: what the company says
Our Novartis R&D leaders, Fiona Marshall ... have defined a clear strategy for how these technological advances should be integrated from end-to-end, across the R&D continuum.Story: Smarter decisions at scale: How Novartis is using AI to advance R&D, 28 Jul 2026Scaling AI across the value chain to unlock productivity and performance ... Target Discovery Engine ... Small molecule GenChem and optimizationMeet Novartis Management 2025 CEO presentation (investor event, London), 20 Nov 2025, p. 29Delivery claimed, claimed: what it shows running
This is playing out in focused initiatives across Novartis R&D: Target identification and validation: AI models can integrate evidence from human genetic and multi-omic datasetsStory: Smarter decisions at scale: How Novartis is using AI to advance R&D, 28 Jul 2026Reviewed AI use case on “New Target Identification”, “Driving Translation through Data Science and AI”, “Present and Future of AI Augmented Chemistry”, and “AI/ML in Biologics”Novartis Annual Report 2025 (Form 20-F format; AR and 20-F counted as one source), 4 Feb 2026, p. 125These efforts are shifting how teams work so they’re spending less time sifting through data and more time on creative iteration and decision-making.Story: Smarter decisions at scale: How Novartis is using AI to advance R&D, 28 Jul 2026Commitments made public in the last 12 months: 3
- Chai Discovery antibody design models New, announced, 13 Jul 2026, source: partner release, company quoted
- Orionis Allo-Glue molecular glue collaboration Expanded, announced, 10 Jun 2026, source: partner release, company quoted
- Relation Therapeutics atopic disease target discovery New, announced, 9 Dec 2025, source: partner release, company quoted
Prior 12 months: 5. Search coverage: partial.
R&D roles open on 6 Oct 2026: 8
- AI Scientist - AI-Driven Target Identification Basel (City)
- AI Scientist - AI-Driven Target Identification Cambridge (USA)
- Senior Specialist, Data Science & AI Cambridge (USA)
- Computational Medicinal Chemist LaJolla/SD
- Data Scientist, AI for Biomedical Imaging Cambridge (USA)
- Data Science, Cheminformatics & AI: Lab-in-the-Loop Hit Finding San Diego
and 2 more in the company brief.
Showing up to three quotes for each score. Observed activity is a count of public signals, not a score, and search coverage varies by company. The full account brief for Novartis lists every source.
Pfizerbuild underway
Priority 5 / Delivery claimed
Observed activity: 5 new · 4 roles
Priority 5: what the company says
Our 2026 key priorities are: ... Scale AI across our business.Pfizer 2025 Form 10-K, 26 Feb 2026, p. 10In addition, we are scaling AI across R&D, manufacturing, commercial and patient engagement to improve productivity and accelerate innovation.Pfizer 2025 Form 10-K, 26 Feb 2026, p. 10Build an end-to-end AI-native R&D organizationQ2 2026 earnings charts, 4 Aug 2026, p. 9Delivery claimed, build underway: what it shows running
To meet the growing AI demand, over the next two years, we are expanding to more than 1,200 GPUs, largely driven by R&D application of AI.Q4 2025 earnings call prepared remarks, 3 Feb 2026, p. 3We are embedding AI into each functional line in R&D.Q1 2026 earnings call prepared remarks, 5 May 2026, p. 5It's going to be by deploying AI, which already happened in 2025 with excellent results that creates significant productivity gains. This is where we are reducing the cost of R&D.Q4 2025 Pfizer Inc Earnings Call transcript (LSEG edited, company-hosted), 3 Feb 2026, p. 14Commitments made public in the last 12 months: 5
- Chai Discovery platform licence New, announced, 2 Jun 2026, source: partner only
- R&D AI compute expansion (GPUs) New, announced, 3 Feb 2026, source: company
- LIGAND-AI IHI consortium (open protein-ligand data for AI) New, in build, 20 Jan 2026, source: joint release
- Pfizer Ventures: Enodia Therapeutics New, announced, 15 Jan 2026, source: third party
- Boltz biomolecular foundation models New, announced, 8 Jan 2026, source: joint release
Prior 12 months: 3. Search coverage: partial.
R&D roles open on 6 Oct 2026: 4
- Senior AI/ML Engineer - Research Data AI and Predictive Modeling (Vaccine R&D) Pearl River, NY, US
- Principal ML/AI Cheminformatics Scientist Groton, CT, US
- Senior ML/AI Cheminformatics Scientist Groton, CT, US
- AI Oncology Portfolio Lead (Director) San Diego, CA, US
Showing up to three quotes for each score. Observed activity is a count of public signals, not a score, and search coverage varies by company. The full account brief for Pfizer lists every source.
Takedafunded or contracted
Priority 4 / Delivery 2
Observed activity: 5 new · 16 roles
Priority 4: what the company says
We seek to achieve a foundational shift that embeds AI into every stage of drug discovery, redesigning workflows to include automated, data-driven, predictive processes that accelerate innovation.Takeda Annual Report on Form 20-F for FY2025 (year ended 31 March 2026), 17 Jun 2026, p. 25By using advanced models to predict how molecules will behave, we can identify high-quality candidates earlier and rapidly optimize their design.Takeda 2026 Annual Integrated Report (FY2025), 27 Jun 2026, p. 8Through bold investments in digital, data and AI-driven capabilities, our teams are delivering for patients at speed and scale.Takeda 2026 Annual Integrated Report (FY2025), 27 Jun 2026, p. 8Delivery 2, funded or contracted: what it shows running
Iambic Therapeutics U.S. Cross-therapeutic area discovery research alliance to leverage Iambic’s computational-driven discovery engineTakeda Annual Report on Form 20-F for FY2025 (year ended 31 March 2026), 17 Jun 2026, p. 49By using advanced models to predict how molecules will behave, we can identify high-quality candidates earlier and rapidly optimize their design.Takeda 2026 Annual Integrated Report (FY2025), 27 Jun 2026, p. 8Commitments made public in the last 12 months: 5
- Insilico Medicine Pharma.AI collaboration New, announced, 1 Jul 2026, source: partner release, company quoted
- Labs of Tomorrow (AIRx, DAR, automated discovery labs) New, in build, 27 Jun 2026, source: company
- Boltz biomolecular foundation model platform deployment New, announced, 18 Jun 2026, source: partner release, company quoted
- Iambic AI small-molecule collaboration New, announced, 9 Feb 2026, source: partner release, company quoted
- Nabla Bio second AI protein design collaboration (JAM platform) New, announced, 14 Oct 2025, source: partner release, company quoted
Prior 12 months: 1. Search coverage: partial.
R&D roles open on 6 Oct 2026: 16
- Head of Biologics Engineering & Next-Generation Platform Innovation Boston, Massachusetts, United States
- Associate Director, AI/ML (Biologics) Boston, Massachusetts, United States
- Lead Product Owner, Labs of Tomorrow Small Molecule Boston, Massachusetts, United States
- Technical Product Owner, AI-native Large molecule Discovery Boston, Massachusetts, United States
- Associate Director or Senior Scientist, Computational Chemistry, Research Fujisawa, Kanagawa, Japan
- Senior Director, AIRx DMPK & Modeling Lead Boston, Massachusetts, United States
and 10 more in the company brief.
Technology named in these postings
Named as in use: SAIL (TetraScience programme), TetraScience
Asked for as experience: Python
Showing up to three quotes for each score. Observed activity is a count of public signals, not a score, and search coverage varies by company. The full account brief for Takeda lists every source.
Gileadclaimed
Priority 2 / Delivery claimed
Observed activity: 0 new · 2 roles
Priority 2: what the company says
Gilead will build and maintain leadership capabilities to govern AI responsibly while applying these powerful new tools to support drug discovery, improve the employee experience and expedite responsible business reporting efforts.2025 Responsible Business and Impact Report, 21 Apr 2026, p. 10Brings Together Oncology, Inflammation and Research Data Science Teams to Foster Scientific CollaborationGilead Opens State-of-the-Art Research Center to Advance the Next Generation of Medicines, 8 Sep 2026Adopt and Scale AI to Transform How We Work2026 Notice of Annual Meeting and Proxy Statement with Form 10-K for FY2025 (annual report wrapper), 20 Mar 2026, p. 2Delivery claimed, claimed: what it shows running
today celebrated the opening of its 182,000-square-foot Research Center at its Foster City headquarters, expanding capabilities in oncology, inflammation and research data scienceGilead Opens State-of-the-Art Research Center to Advance the Next Generation of Medicines, 8 Sep 2026By co-locating key research disciplines and expanding our data science capabilities, we are strengthening the infrastructure needed to accelerate discovery and advance meaningful innovations.Gilead Opens State-of-the-Art Research Center to Advance the Next Generation of Medicines, 8 Sep 2026Commitments made public in the last 12 months: 0
None identified in the reviewed sources.
Prior 12 months: 1. Search coverage: partial.
R&D roles open on 6 Oct 2026: 2
- Senior Scientist, AI/ML (Biologics Design) United States - California - Foster City
- AI Data Science Lead - Research (Gilead & Kite) United States - North Carolina - Raleigh
Technology named in these postings
Asked for as experience: Python
Showing up to three quotes for each score. Observed activity is a count of public signals, not a score, and search coverage varies by company. The full account brief for Gilead lists every source.
Daiichi Sankyolive
Priority 8 / Delivery 4
Observed activity: 2 new · 3 roles
Priority 8: what the company says
Expanding Drug Discovery Research Capabilities: Creation of BGTs through the integration of expanded research functions, digital transformation (DX) of drug discovery research, and open innovationFY2025 Financial Results and 5-Year Business Plan Presentation (FY2026-FY2030), 11 May 2026, p. 69Opening of Smart Research Lab San Diego ... Building AWS infrastructure and data utilization systems ... Completion of new research building (Smart Lab)FY2025 Financial Results and 5-Year Business Plan Presentation (FY2026-FY2030), 11 May 2026, p. 69Launched Smart Research Lab in San Diego to Accelerate Innovation ... Integrated robotic automation for end-to-end workflows ... DS’s first dedicated drug discovery base in the U.S.Science & Technology Day 2025, 16 Dec 2025, p. 86Delivery 4, live: what it shows running
実験装置にAIを組み込み、これまで人が目視で行っていた液体の量の測定や ... リアルタイムで自動的に行えるようになりました。これにより、実験操作の一部が自動化され、作業の正確性と効率が向上しています。[Ortent translation: AI has been built into laboratory equipment, so that measuring liquid volumes, which people used to do by eye, ... can now be done automatically in real time. Part of the experimental work is now automated, which has improved its accuracy and efficiency.]
DX - データと先進デジタル技術の活用 (DX corporate page), No printed date. Its content dates it to Jul 2026 or later, and we read it on 6 Oct 2026研究者が設計した多様な実験工程をロボットで実行します。 ... 「メタデータ」を取得し、実験結果とともにデータプロダクトとして標準化して保存します。実験結果を電子ノートへまとめる仕組みも整備しています。[Ortent translation: Robots carry out the varied experimental steps our researchers design. ... "metadata" is captured and stored, standardised as a data product together with the experimental results. We have also set up a system to compile experimental results into electronic notebooks.]
DX - データと先進デジタル技術の活用 (DX corporate page), No printed date. Its content dates it to Jul 2026 or later, and we read it on 6 Oct 2026At the SRL, advanced robotics and in-house developed, sophisticated software is being utilized to significantly enhance the efficiency of drug discovery researchAdvancing Research for the Future: The Potential of Smart Research Laboratories in Research DX, 31 Oct 2025Commitments made public in the last 12 months: 2
- New Shinagawa research building (Smart Lab) New, announced, 11 May 2026, source: company
- Smart Research Laboratories I and II (Research Division units) New, operational, 24 Feb 2026, source: company
Prior 12 months: 1. Search coverage: partial.
R&D roles open on 6 Oct 2026: 3
- Automation engineer (research instrument automation and instrument software engineering) DSHQ オートメーションエンジニア(研究機器自動化、機器関連ソフトウエアエンジニアリング), Tokyo, Japan (Shinagawa)
- Software engineer (in-house research software) DSHQ ソフトウエアエンジニア(社内研究向けソフトウエア), Tokyo, Japan (Shinagawa)
- High-throughput synthesis (automated synthesis and lab automation) DSHQ ハイスループット合成(自動合成・ラボオートメーション), Tokyo, Japan (Shinagawa)
Technology named in these postings
Asked for as experience: SiLA 2, AWS, UNIX/Linux
Showing up to three quotes for each score. Observed activity is a count of public signals, not a score, and search coverage varies by company. The full account brief for Daiichi Sankyo lists every source.
Regeneronlive
Priority 8 / Delivery 4
Observed activity: 0 new · 4 roles
Priority 8: what the company says
Integrating Genetics, Proteomics, and Big Data ... World’s largest DNA and proteomics-linked healthcare database, enabling advanced drug discovery, development, and healthcare analyticsRegeneron Corporate Presentation, January 2026, Jan 2026, p. 3Integrating Genetics, Proteomics, and Big Data ... World's largest DNA and proteomics-linked healthcare database, enabling advanced drug discovery, development, and healthcare analyticsRegeneron Corporate Presentation, July 2026, Jul 2026, p. 3over the last decade, we have made enormous investments to build the world's largest collection of "big data" in which de-identified electronic health records ("EHRs") are linked to molecular data (DNA sequence and proteomics data).2026 Proxy Statement (DEF 14A), 24 Apr 2026Delivery 4, live: what it shows running
RGC utilizes laboratory automation and innovative approaches to cloud computing to achieve high-quality throughput, attaining over 3 million samples sequenced to date.Regeneron 2025 Annual Report incl. Form 10-K FY2025, 4 Feb 2026, p. 22we partnered with DNAnexus to provide infrastructure ... today, it underpins everything from large-scale sequencing projects to trusted research environments used by global collaborationsStrategic Investments for a Stronger RGC Future (story), 13 Jan 2026We are also introducing more automation to improve coverage uniformity, and re-engineer bioinformatics workflows so sequencing data can be analyzed even faster.Strategic Investments for a Stronger RGC Future (story), 13 Jan 2026Commitments made public in the last 12 months: 0
None identified in the reviewed sources.
Prior 12 months: 0. Search coverage: partial.
R&D roles open on 6 Oct 2026: 4
- Senior Developer - Research and Development TARRYTOWN
- Associate Director Solutions Partner (Scientific Data Product Owner) TARRYTOWN
- Associate Manager Next-Generation Sequencing (NGS) Data Analysis TARRYTOWN
- Senior Director - Research Solutions Hyderabad
Technology named in these postings
Named as in use: Sapio, Benchling, Dotmatics
Asked for as experience: Databricks
Showing up to three quotes for each score. Observed activity is a count of public signals, not a score, and search coverage varies by company. The full account brief for Regeneron lists every source.
Amgenlive
Priority 6 / Delivery 4
Observed activity: 1 new · 14 roles
Priority 6: what the company says
Marti Head, Associate Vice President, Automation, Research Data Systems, Informatics, and AIAmgen's Approach to AI-Enabled Clinical Development, 20 May 2026$125M investment expands Amgen's South San Francisco research hub ... Integrated labs bring medicinal chemistry, biology, protein sciences, automation, and data science together to accelerate discoveryInside Amgen's Next-Generation Labs: Powering Faster, Smarter Small Molecule Drug Discovery, 6 May 2026the labs are purpose-built to support more than 100 scientists and equipped with advanced technologies ... from high-throughput automation and robotics to state-of-the-art analytical toolsInside Amgen's Next-Generation Labs: Powering Faster, Smarter Small Molecule Drug Discovery, 6 May 2026Delivery 4, live: what it shows running
the labs are purpose-built to support more than 100 scientists and equipped with advanced technologies ... from high-throughput automation and robotics to state-of-the-art analytical toolsInside Amgen's Next-Generation Labs: Powering Faster, Smarter Small Molecule Drug Discovery, 6 May 2026AI designs proteins with desired properties. Robots make and test them at scale. Results feed back into the AI model, improving its predictions.Bio Meets Tech: How Amgen is Designing the Medicines of Tomorrow, 2 Dec 2025High-throughput automation further minimizes bottlenecks, scales operations efficiently and helps Amgen bring more potential therapeutics forward faster.Bio Meets Tech: How Amgen is Designing the Medicines of Tomorrow, 2 Dec 2025Commitments made public in the last 12 months: 1
- South San Francisco small-molecule discovery labs ($125M) New, operational, 6 May 2026, source: company
Prior 12 months: 0. Search coverage: partial.
R&D roles open on 6 Oct 2026: 14
- Principal Scientist - AI/ML Workflow & Ecosystem Lead (Large Molecule Discovery Informatics) Hyderabad, India
- Product Manager, R&D Data Catalyst Team India - Hyderabad
- Associate Scientist - Digital Discovery: Antibody Bioinformatics Burnaby, British Columbia, Canada
- Sr Associate Software Engineer - Biological Studies (LIMS) Hyderabad, India
- Sr Semantic Software Engineer - Research Data and Analytics Hyderabad, India
- Sr Scientist - Business Owner, Data Automation Hyderabad, India
and 8 more in the company brief.
Technology named in these postings
Named as in use: Research Controlled Vocabulary Foundation (Amgen internal platform)
Asked for as experience: AWS, Databricks, MLflow, Git, Signals, Docker
Showing up to three quotes for each score. Observed activity is a count of public signals, not a score, and search coverage varies by company. The full account brief for Amgen lists every source.
Astellaslive
Priority 5 / Delivery 4
Observed activity: 1 new · 1 role
Priority 5: what the company says
A key initiative at Astellas is to enhance our global data infrastructure and governance to enable further AI adoptionIntegrated Report 2025 (FY2024, English), 31 Oct 2025, p. 62by actively promoting the use of data, including the proactive utilization of real-world data, integration of R&D database, and AI-driven simulation and modeling, we are working to speed upAstellas R&D Day event transcript, 31 March 2026, 31 Mar 2026, p. 17but also by introducing AI-enabled protein station for research automationAstellas R&D Day event transcript, 31 March 2026, 31 Mar 2026, p. 19Delivery 4, live: what it shows running
It also includes automated synthesis and assay systems using robots, and tools ... for automatically creating structure-activity relationship (SAR) tables ... The platform also ... incorporates the ability to remotely monitor the operation of the robotsIntegrated Report 2025 (FY2024, English), 31 Oct 2025, p. 61we are building and enhancing ... dedicated in-house databases for each modality. Furthermore, the deployment ... of robotic technology to our overseas and joint research facilities is progressing, ... creating a global network to collect more uniform, high-quality dataIntegrated Report 2025 (FY2024, English), 31 Oct 2025, p. 62but also by introducing AI-enabled protein station for research automationAstellas R&D Day event transcript, 31 March 2026, 31 Mar 2026, p. 19Commitments made public in the last 12 months: 1
- AI-enabled Protein Station for biologics discovery automation New, announced, 31 Mar 2026, source: company
Prior 12 months: 0. Search coverage: partial.
R&D roles open on 6 Oct 2026: 1
- Senior Research Associate MA, Westborough
Technology named in these postings
Named as in use: Illumina sequencing platforms, Oxford Nanopore sequencing platforms
Showing up to three quotes for each score. Observed activity is a count of public signals, not a score, and search coverage varies by company. The full account brief for Astellas lists every source.
AstraZenecalive
Priority 5 / Delivery 4
Observed activity: 0 new · 8 roles
Priority 5: what the company says
The R&D centre includes ten floors of interconnecting laboratories to allow a flow of seamless science enabled by cutting-edge technologies that integrate robotics, continuous automation, and agentic AI.AstraZeneca opens new global strategic R&D centre in Kendall Square, Cambridge, Massachusetts, 5 Oct 2026AstraZeneca today announced the opening of its newest global strategic research and development (R&D) centre, in Kendall SquareAstraZeneca opens new global strategic R&D centre in Kendall Square, Cambridge, Massachusetts, 5 Oct 2026ten floors of interconnecting laboratories to allow a flow of seamless science enabled by cutting-edge technologies that integrate robotics, continuous automation, and agentic AIAstraZeneca opens new global strategic R&D centre in Kendall Square, Cambridge, Massachusetts, 5 Oct 2026Delivery 4, live: what it shows running
AstraZeneca today announced the opening of its newest global strategic research and development (R&D) centre, in Kendall SquareAstraZeneca opens new global strategic R&D centre in Kendall Square, Cambridge, Massachusetts, 5 Oct 2026The R&D centre includes ten floors of interconnecting laboratories to allow a flow of seamless science enabled by cutting-edge technologies that integrate robotics, continuous automation, and agentic AI.AstraZeneca opens new global strategic R&D centre in Kendall Square, Cambridge, Massachusetts, 5 Oct 2026$171m expense within Research and development expense in relation to severance as well as the transformation of clinical, regulatory and other R&D data and systems.AstraZeneca Annual Report & Form 20-F Information 2025, 18 Feb 2026, p. 144Commitments made public in the last 12 months: 0
None identified in the reviewed sources.
Prior 12 months: 0. Search coverage: partial.
R&D roles open on 6 Oct 2026: 8
- Agentic AI Sr. Engineer Cambridge, MA or Gaithersburg, MD, US
- Associate Director, Digital Proteomics and AI Innovation Gaithersburg, Maryland, US
- Data Engineering Lead (Drug Discovery Data Platform) Barcelona, Spain
- Scientist, High Throughput Antibody Production Cambridge, Massachusetts, US
- Biocentre Automation Technician Gaithersburg, Maryland, US
- Senior Engineer - Biobank IT Support Chennai, India, posting since closed
and 2 more in the company brief.
Technology named in these postings
Named as in use: AWS, PostgreSQL, Snowflake, Claude Code, Claude Cowork, Confluence, Domino, GitHub, GitHub Copilot, Hugging Face, Kubernetes, M365 Copilot
Showing up to three quotes for each score. Observed activity is a count of public signals, not a score, and search coverage varies by company. The full account brief for AstraZeneca lists every source.
GSKlive
Priority 5 / Delivery 4
Observed activity: 0 new · 3 roles
Priority 5: what the company says
In 2025, we accelerated and expanded the deployment of advanced data and platform technologies end-to-end in R&D.GSK Annual Report 2025, 5 Mar 2026, p. 34by integrating advanced computational protein modelling with an end-to-end automated lab-in-the-loop platform. This closes the design-build-test cycle so we can reliably deliver therapeutic large molecules, faster.GSK Annual Report 2025, 5 Mar 2026, p. 34our AI/ML-powered lab-in-the-loop automated systems, which scale experimentation and reduce resource duplication, are redefining how we optimise therapies in HIV and immunology.GSK Annual Report 2025, 5 Mar 2026, p. 35Delivery 4, live: what it shows running
by integrating advanced computational protein modelling with an end-to-end automated lab-in-the-loop platform. This closes the design-build-test cycle so we can reliably deliver therapeutic large molecules, faster.GSK Annual Report 2025, 5 Mar 2026, p. 34our AI/ML-powered lab-in-the-loop automated systems, which scale experimentation and reduce resource duplication, are redefining how we optimise therapies in HIV and immunology.GSK Annual Report 2025, 5 Mar 2026, p. 35In 2025, we accelerated and expanded the deployment of advanced data and platform technologies end-to-end in R&D.GSK Annual Report 2025, 5 Mar 2026, p. 34Commitments made public in the last 12 months: 0
None identified in the reviewed sources.
Prior 12 months: 0. Search coverage: partial.
R&D roles open on 6 Oct 2026: 3
- Senior Director, CMC & Lab Specialization Cambridge, Massachusetts, United States of America
- Lab Robotics Manager Cambridge, Massachusetts, United States of America
- Lab Data Manager Cambridge, Massachusetts, United States of America
Technology named in these postings
Named as in use: MyLabData
Showing up to three quotes for each score. Observed activity is a count of public signals, not a score, and search coverage varies by company. The full account brief for GSK lists every source.
Modernalive
Priority 5 / Delivery 4
Observed activity: 0 new · 4 roles
Priority 5: what the company says
Power innovation through our Scientific Intelligence Engine Harness data, AI/ML, automation, and robotics to accelerate discovery and continuously improve how we workModerna Science Day 2026 presentation, 25 Jun 2026, p. 116Learning at scale requires a fundamentally different experimentation and data infrastructureModerna Science Day 2026 presentation, 25 Jun 2026, p. 107This really requires fundamentally changing the way that we do experimentation and also the data infrastructure that is required to take the data in and make it usable for all of our modern AI tools.Moderna Science Day transcript (LSEG StreetEvents), 25 Jun 2026, p. 25Delivery 4, live: what it shows running
High-throughput automation and custom engineered equipment allow us to produce and deliver high quality mRNA and formulated constructs ... our proprietary platform is capable of producing up to 1,000 lots of mRNA sequences and formulations per monthModerna Form 10-K for fiscal year ended 31 December 2025, 20 Feb 2026, p. 24a series of in vitro based assays and that is what we do within a closed-loop platform ... We've built platforms that allow us to do in vivo multiplex screening in mice and in nonhuman primates.Moderna Science Day transcript, 25 June 2026, 25 Jun 2026, p. 26This has been possible, in part, due to the ability of researchers in the Moderna ecosystem to order constructs through an integrated digital portal that tracks materials end-to-end in less than 45 days.Moderna Form 10-K for fiscal year ended 31 December 2025, 20 Feb 2026, p. 24Commitments made public in the last 12 months: 0
None identified in the reviewed sources.
Prior 12 months: 1. Search coverage: partial.
R&D roles open on 6 Oct 2026: 4
- Integration Lead, Bioassay COE Norwood, Massachusetts (MTC North - Norwood - USA - MA)
- Principal Systems Engineer, Digital Lab Systems Norwood, Massachusetts (MTC South - Norwood - USA - MA)
- Sr. Director, Software Engineering, Digital for Research & CMC Development Cambridge, Massachusetts (325 Binney St - Cambridge - USA - MA)
- Product Manager, Digital for Research and Tech Dev Norwood, Massachusetts (MTC North - Norwood - USA - MA)
Technology named in these postings
Named as in use: Chromeleon, Hamilton, LabX, Scitara DLX, Hamilton liquid handling platforms, Hamilton VENUS, Benchling
Asked for as experience: SoftMax
Showing up to three quotes for each score. Observed activity is a count of public signals, not a score, and search coverage varies by company. The full account brief for Moderna lists every source.
Novartislive
Priority 5 / Delivery 4
Observed activity: 1 new · 10 roles
Priority 5: what the company says
As Chief Data and Digital Officer, I’m driven by the idea that data science and AI can help us understand diseaseStory: The Day AI Made Me Rethink What Science Could Do (Christian Diehl), 23 Sep 2026That question led me to develop what became Data42 within Biomedical ResearchStory: The Day AI Made Me Rethink What Science Could Do (Christian Diehl), 23 Sep 2026Delivery 4, live: what it shows running
Today, I’m proud to say that Data42 underpins our growing ecosystem of AI-driven research. By connecting clinical, molecular, preclinical and biology data, it enables us to tackle scientific questions across domainsStory: The Day AI Made Me Rethink What Science Could Do (Christian Diehl), 23 Sep 2026Commitments made public in the last 12 months: 1
- CAS AI-ready reaction informatics New, announced, 29 Sep 2026, source: partner only
Prior 12 months: 1. Search coverage: partial.
R&D roles open on 6 Oct 2026: 10
- Data Scientist, AI for Biomedical Imaging Cambridge (USA)
- Data Science, Cheminformatics & AI: Lab-in-the-Loop Hit Finding San Diego
- Research Scientist II, Laboratory Automation & Drug Discovery Support Basel (City)
- Senior Automation Engineer, High-Throughput Screening Cambridge (USA)
- Forward Deployed Engineer (FDE) Data42 (Palantir Foundry) Cambridge (USA)
- Forward Deployed Engineer (FDE) Data42 (Palantir Foundry) Basel (City)
and 4 more in the company brief.
Technology named in these postings
Named as in use: Data42, Palantir Foundry
Asked for as experience: Beckman Echo, Biosero Orchestrator, Cellario, CellTrio RoboCell, Denso robots, GNF Director, Green Button Go, HighRes Biosolutions, Staubli robots
Showing up to three quotes for each score. Observed activity is a count of public signals, not a score, and search coverage varies by company. The full account brief for Novartis lists every source.
Rochelive
Priority 5 / Delivery 4
Observed activity: 1 new · 7 roles
Priority 5: what the company says
R&D Excellence: Our solutions Moving from implementation to “business as usual” ... Build a simplified system landscape and data foundationRoche Pharma Day 2026 presentation, 28 Sep 2026, p. 49Our ‘R&D Excellence’ initiative, launched two years ago to accelerate our research and development, is showing strong progress.Roche Annual Report 2025, 29 Jan 2026, p. 12Towards autonomous labs for drug R&D Our Autonomous Lab Accelerator to enhance the loopRoche Pharma Day 2026 presentation, 28 Sep 2026, p. 94Delivery 4, live: what it shows running
Medra's platform integrates with Genentech’s internal ML infrastructure and its laboratory information management systemGenentech story: AI Fuels Genentech's R&D Ecosystem, 9 Jan 2026Medra physical AI, MHS (Anthropic) Autonomous Lab AcceleratorRoche Pharma Day 2026 presentation, 28 Sep 2026, p. 71Build a simplified system landscape and data foundation Implemented and moving into business as usual Implementation in progressRoche Pharma Day 2026 presentation, 28 Sep 2026, p. 49Commitments made public in the last 12 months: 1
- Medra physical AI lab collaboration New, operational, 11 Dec 2025, source: company
Prior 12 months: 0. Search coverage: partial.
R&D roles open on 6 Oct 2026: 7
- Senior Software Engineer, Research Biology South San Francisco, California, United States of America
- Senior Machine Learning Engineer - AI Enablement Welwyn, Hertfordshire, United Kingdom
- Principal / Senior Principal Software Engineer Basel, Switzerland
- Machine Learning Engineer - AI Enablement Welwyn, Hertfordshire, United Kingdom
- Lab Automation - Digital Solution Lead South San Francisco, California, United States of America
- Senior Software Engineer Lab Automation Basel, Basel-City, Switzerland
and 1 more in the company brief.
Technology named in these postings
Named as in use: AWS
Asked for as experience: Kubernetes
Showing up to three quotes for each score. Observed activity is a count of public signals, not a score, and search coverage varies by company. The full account brief for Roche lists every source.
Pfizerbuild underway
Priority 5 / Delivery 3
Observed activity: 0 new · 3 roles
Priority 5: what the company says
We have been setting the foundation with AI-ready data, agentic workflows and compute capacity.Q4 2025 earnings call prepared remarks, 3 Feb 2026, p. 3Pfizer has a vast repository of small and large molecule, translational and clinical data and AI is creating the opportunity to unlock insightsQ1 2026 earnings call prepared remarks, 5 May 2026, p. 5Delivery 3, build underway: what it shows running
Progress with making petabytes of data AI readyQ2 2026 earnings charts, 4 Aug 2026, p. 9Commitments made public in the last 12 months: 0
None identified in the reviewed sources.
Prior 12 months: 0. Search coverage: partial.
R&D roles open on 6 Oct 2026: 3
- Senior AI/ML Engineer - Research Data AI and Predictive Modeling (Vaccine R&D) Pearl River, NY, US
- Head of Immunodiagnostics and Next Generation Technology Pearl River, NY, US
- Senior Research Scientist, High Content Imaging Groton, CT, US
Showing up to three quotes for each score. Observed activity is a count of public signals, not a score, and search coverage varies by company. The full account brief for Pfizer lists every source.
Eli Lillyfunded or contracted
Priority 5 / Delivery 2
Observed activity: 1 new · 13 roles
Priority 5: what the company says
The collaboration will initially focus on creating a continuous learning system that tightly connects Lilly's agentic wet labs with computational dry labs, enabling 24/7 AI-assisted experimentation to support biologists and chemists.NVIDIA and Lilly Announce Co-Innovation AI Lab to Reinvent Drug Discovery in the Age of AI (joint release), 12 Jan 2026NVIDIA and Lilly will pioneer robotics and physical AI to accelerate and scale medicine discovery and production.NVIDIA and Lilly Announce Co-Innovation AI Lab to Reinvent Drug Discovery in the Age of AI (joint release), 12 Jan 2026allowing them to work side by side to generate large-scale data and build powerful AI models that can accelerate medicine developmentNVIDIA and Lilly Announce Co-Innovation AI Lab to Reinvent Drug Discovery in the Age of AI (joint release), 12 Jan 2026Delivery 2, funded or contracted: what it shows running
The collaboration will initially focus on creating a continuous learning system that tightly connects Lilly's agentic wet labs with computational dry labs, enabling 24/7 AI-assisted experimentation to support biologists and chemists.NVIDIA and Lilly Announce Co-Innovation AI Lab to Reinvent Drug Discovery in the Age of AI (joint release), 12 Jan 2026The two companies will invest up to $1 billion in talent, infrastructure and compute over five years to support the new AI co-innovation lab.NVIDIA and Lilly Announce Co-Innovation AI Lab to Reinvent Drug Discovery in the Age of AI (joint release), 12 Jan 2026The two companies will invest up to $1 billion in talent, infrastructure and compute over five years to support the new AI co-innovation lab.NVIDIA and Lilly Announce Co-Innovation AI Lab to Reinvent Drug Discovery in the Age of AI (joint release), 12 Jan 2026Commitments made public in the last 12 months: 1
- Lilly AI factory (LillyPod) and NVIDIA AI co-innovation lab Expanded, announced, 12 Jan 2026, source: joint release
Prior 12 months: 0. Search coverage: partial.
R&D roles open on 6 Oct 2026: 13
- Lab Analytical Automation Scientist Shanghai, Shanghai, China
- Advisor - Lab Automation Software Engineer San Diego, California, United States of America
- Advisor - Lab Automation Software Engineer, AI-Integration San Diego, California, United States of America
- RNA Automation Project Lead Shanghai, Shanghai, China
- RNA Automation Specialist (NGS sequencing Focus) Shanghai, Shanghai, China
- RNA Automation Specialist (Biology Focus) Shanghai, Shanghai, China
and 7 more in the company brief.
Technology named in these postings
Named as in use: Hamilton, Tecan, Opentrons, AWS, Kubernetes, Docker, Kubernetes/EKS, Jenkins, Model Context Protocol (MCP)
Asked for as experience: Cellario
Showing up to three quotes for each score. Observed activity is a count of public signals, not a score, and search coverage varies by company. The full account brief for Eli Lilly lists every source.
AbbVielive
Priority 3 / Delivery 4
Observed activity: 0 new · 9 roles
Priority 3: what the company says
Through our areas of innovation, which include data convergence, artificial intelligence (AI), genetic medicine and genomics, patient-focused disease medicine and therapeutic modalities, we are leveraging powerful tools in order to accelerate discoveryAbbVie 2025 ESG Action Report, No printed date. Its content dates it to 23 Mar 2026 or later, and we read it on 6 Oct 2026, p. 17Data convergence: We have integrated data across our areas of expertise through technology into a unified knowledge platform, improving how we collect, analyze and apply data to generate insights fasterAbbVie 2025 ESG Action Report, No printed date. Its content dates it to 23 Mar 2026 or later, and we read it on 6 Oct 2026, p. 18Delivery 4, live: what it shows running
Data convergence: We have integrated data across our areas of expertise through technology into a unified knowledge platform, improving how we collect, analyze and apply data to generate insights fasterAbbVie 2025 ESG Action Report, No printed date. Its content dates it to 23 Mar 2026 or later, and we read it on 6 Oct 2026, p. 18We are centralizing and connecting data from more than 170 internal and external sources, enabling us to more quickly generate comprehensive insights to inform R&D.AbbVie 2025 ESG Action Report, No printed date. Its content dates it to 23 Mar 2026 or later, and we read it on 6 Oct 2026, p. 18Commitments made public in the last 12 months: 0
None identified in the reviewed sources.
Prior 12 months: 0. Search coverage: partial.
R&D roles open on 6 Oct 2026: 9
- Senior Scientist I - Bioinformatics, Biotherapeutics and Genetic Medicine Worcester, MA
- Scientist- Bioinformatics, Biotherapeutics and Genetic Medicine Worcester, MA
- China AI/ML, Automation, and Capability Expansion Lead, Biotherapeutics and Genetic Medicine Shanghai, Shanghai
- Manager, Data Products & Delivery North Chicago, IL
- HPC Architect North Chicago, IL, posting since closed
- Data Engineer, AI Enablement North Chicago, IL
and 3 more in the company brief.
Technology named in these postings
Named as in use: ARCH (AbbVie R&D Convergence Hub), Posit Connect, Posit Package Manager, Posit Workbench, Slurm, ARCH knowledge graph (R&D Convergence Hub)
Asked for as experience: AWS, Apptainer/Singularity, Mellanox/NVIDIA InfiniBand, NVIDIA GPUs and CUDA
Showing up to three quotes for each score. Observed activity is a count of public signals, not a score, and search coverage varies by company. The full account brief for AbbVie lists every source.
Merck KGaAbuild underway
Priority 3 / Delivery 3
Observed activity: 0 new · 1 role
Priority 3: what the company says
We are continuing to build our automated design-make-test-analyze platform powered by lab automation and AIDDISON2025 Annual Report of Merck KGaA, Darmstadt, Germany (2025-Q4-Report-NA.pdf), 5 Mar 2026, p. 41Delivery 3, build underway: what it shows running
We are continuing to build our automated design-make-test-analyze platform powered by lab automation and AIDDISON2025 Annual Report of Merck KGaA, Darmstadt, Germany (2025-Q4-Report-NA.pdf), 5 Mar 2026, p. 41Commitments made public in the last 12 months: 0
None identified in the reviewed sources.
Prior 12 months: 0. Search coverage: partial.
R&D roles open on 6 Oct 2026: 1
- Principal Scientist, Synthetic & Discovery Chemistry Billerica, Massachusetts, United States
Showing up to three quotes for each score. Observed activity is a count of public signals, not a score, and search coverage varies by company. The full account brief for Merck KGaA lists every source.
Bristol Myers Squibbfunded or contracted
Priority 2 / Delivery 2
Observed activity: 0 new · 2 roles
Priority 2: what the company says
For Mr. Meyers, in the role of Chief Digital & Technology Officer, the Committee considered his: (i) leadership in driving transformation and innovation at scale across the business, and in simplifying and strengthening scientific and digital foundationsBristol Myers Squibb 2026 Proxy Statement, 25 Mar 2026, p. 73Connecting Claude to the institutional knowledge that lives across BMS. Through secure integrations with the systems and repositories where BMS' scientific, clinical, regulatory, and commercial expertise residesBMS Announces Strategic Agreement with Anthropic to Position Claude Enterprise as the Shared Intelligence Platform, 20 May 2026today announced a strategic agreement with Anthropic to deploy Claude across the company's research, clinical development, manufacturing, commercial, and corporate functionsBMS Announces Strategic Agreement with Anthropic to Position Claude Enterprise as the Shared Intelligence Platform, 20 May 2026Delivery 2, funded or contracted: what it shows running
today announced a strategic agreement with Anthropic to deploy Claude across the company's research, clinical development, manufacturing, commercial, and corporate functionsBMS Announces Strategic Agreement with Anthropic to Position Claude Enterprise as the Shared Intelligence Platform, 20 May 2026Connecting Claude to the institutional knowledge that lives across BMS. Through secure integrations with the systems and repositories where BMS' scientific, clinical, regulatory, and commercial expertise residesBMS Announces Strategic Agreement with Anthropic to Position Claude Enterprise as the Shared Intelligence Platform, 20 May 2026Commitments made public in the last 12 months: 0
None identified in the reviewed sources.
Prior 12 months: 0. Search coverage: partial.
R&D roles open on 6 Oct 2026: 2
- Discovery Research Domain Analyst, IT Business Analyst Princeton - NJ - US
- Senior Scientist, High-Throughput Biologics Production and Discovery Platforms Brisbane - CA - US
Showing up to three quotes for each score. Observed activity is a count of public signals, not a score, and search coverage varies by company. The full account brief for Bristol Myers Squibb lists every source.
Novo Nordiskfunded or contracted
Priority 2 / Delivery 2
Observed activity: 0 new · 2 roles
Priority 2: what the company says
This includes using services such as Amazon Bio Discovery and Amazon Bedrock to identify drug targets, design new therapies faster, and connect genomic, imaging and clinical dataNovo Nordisk and AWS enter strategic partnership to accelerate drug discovery through AI, 10 Aug 2026Research activities further utilise digital scientific methodologies and other technology platformsNovo Nordisk Annual Report 2025 (incl. sustainability statement), 4 Feb 2026, p. 91Faster, standardised ... execution ... Simplifying and automating core ... processesCapital Markets Day 2026: R&D strategy (Lange, Patel), 21 Sep 2026, p. 7Delivery 2, funded or contracted: what it shows running
Agreement establishes AWS as Novo Nordisk's preferred cloud provider and strategic AI partner to accelerate drug discovery and modernise its technology infrastructureNovo Nordisk and AWS enter strategic partnership to accelerate drug discovery through AI, 10 Aug 2026This includes using services such as Amazon Bio Discovery and Amazon Bedrock to identify drug targets, design new therapies faster, and connect genomic, imaging and clinical dataNovo Nordisk and AWS enter strategic partnership to accelerate drug discovery through AI, 10 Aug 2026Research activities further utilise digital scientific methodologies and other technology platformsNovo Nordisk Annual Report 2025 (incl. sustainability statement), 4 Feb 2026, p. 91Commitments made public in the last 12 months: 0
None identified in the reviewed sources.
Prior 12 months: 0. Search coverage: partial.
R&D roles open on 6 Oct 2026: 2
- Principal Scientist, Functional Genomics United Kingdom, Oxford
- Senior Automation & Screening Scientist United Kingdom, Oxford
Showing up to three quotes for each score. Observed activity is a count of public signals, not a score, and search coverage varies by company. The full account brief for Novo Nordisk lists every source.
Boehringer Ingelheimclaimed
Priority 2 / Delivery claimed
Observed activity: 1 new · 1 role
Priority 2: what the company says
embedding computational biology, artificial intelligence (AI), and data excellence into every step of our innovation pipelineComputational Innovation (UK corporate page), 7 Apr 2026On-demand automation of multimodal, analysis-ready datasets across genomics, imaging, and clinical data.Partnering in Computational Innovation flyer (June 2026), 18 Jun 2026, p. 1Delivery claimed, claimed: what it shows running
embedding computational biology, artificial intelligence (AI), and data excellence into every step of our innovation pipelineComputational Innovation (UK corporate page), 7 Apr 2026Commitments made public in the last 12 months: 1
- Lifebit federated Trusted Research Environment Renewed, operational, 1 Sep 2026, source: joint release
Prior 12 months: 0. Search coverage: partial.
R&D roles open on 6 Oct 2026: 1
- Automation Engineer, Lab Automation Ridgefield, CT
Technology named in these postings
Asked for as experience: Python
Showing up to three quotes for each score. Observed activity is a count of public signals, not a score, and search coverage varies by company. The full account brief for Boehringer Ingelheim lists every source.
MSDfunded or contracted
Priority 1 / Delivery 2
Observed activity: 0 new · 2 roles
Priority 1: what the company says
This includes deploying Gemini Enterprise across end-to-end R&D workflowsMerck and Google Cloud Partner to Accelerate Agentic AI Enterprise Transformation, 22 Apr 2026Delivery 2, funded or contracted: what it shows running
This multi-year investment, valued at up to $1 billion, will deploy an agentic platform across Merck's research & development (R&D), manufacturing, commercial, and corporate functionsMerck and Google Cloud Partner to Accelerate Agentic AI Enterprise Transformation, 22 Apr 2026This includes deploying Gemini Enterprise across end-to-end R&D workflowsMerck and Google Cloud Partner to Accelerate Agentic AI Enterprise Transformation, 22 Apr 2026Commitments made public in the last 12 months: 0
None identified in the reviewed sources.
Prior 12 months: 1. Search coverage: partial.
R&D roles open on 6 Oct 2026: 2
- Lead Semantic Data Engineer CZE - Central Bohemian - Prague (Five)
- Senior Technical Product Manager - Integration Platform Prague, Central Bohemian, Czechia
Technology named in these postings
Named as in use: Jira
Asked for as experience: Amazon Web Services (AWS)
Showing up to three quotes for each score. Observed activity is a count of public signals, not a score, and search coverage varies by company. The full account brief for MSD lists every source.
BayerProvisional
Priority 1 / Delivery claimed
Observed activity: 1 new · 2 roles
Priority 1: what the company says
focus on the systematic implementation of digital technologies and the deployment of data sciences to increase the speed, reliability and effectiveness of our R&D processes.Bayer Annual Report 2025 (combined management report, sustainability statement), 4 Mar 2026, p. 45Delivery claimed, claimed: what it shows running
focus on the systematic implementation of digital technologies and the deployment of data sciences to increase the speed, reliability and effectiveness of our R&D processes.Bayer Annual Report 2025 (combined management report, sustainability statement), 4 Mar 2026, p. 45Commitments made public in the last 12 months: 1
- TetraScience Scientific Data Foundry deployment Expanded, announced, 20 Nov 2025, source: partner release, company quoted
Prior 12 months: 0. Search coverage: partial.
R&D roles open on 6 Oct 2026: 2
- Head of Machine Learning Research Whippany,New Jersey,United States
- Head of Machine Learning Research (all genders) Berlin,Berlin,Germany
Provisional: a published company document could not be read in full, so these scores may change. Showing up to three quotes for each score. Observed activity is a count of public signals, not a score, and search coverage varies by company. The full account brief for Bayer lists every source.
Johnson & Johnson
Priority 1 / Delivery none
Observed activity: 0 new · 19 roles
Priority 1: what the company says
Dr. Reed: ... Executive Vice President, Innovative Medicine R&D ... Deepened investment in data science and digital health to accelerate discovery and development across the portfolio.Johnson & Johnson 2026 Proxy Statement (Notice of Annual Meeting and Proxy Statement), 11 Mar 2026, p. 71Delivery none: what it shows running
No company evidence that the work is running was identified in the reviewed sources.
Commitments made public in the last 12 months: 0
None identified in the reviewed sources.
Prior 12 months: 0. Search coverage: partial.
R&D roles open on 6 Oct 2026: 19
- Principal Scientist, Biologics Optimization Spring House, Pennsylvania, United States of America
- Technical Product Manager, Chemistry IT Systems San Diego, California, United States of America, Spring House, Pennsylvania, United States of America
- Associate Director, Expression Sciences Spring House, Pennsylvania, United States of America
- Technical Product Manager, Chemistry IT Systems (linked requisition) see source posting, posting since closed
- Principal Scientist, AI & Autonomous Discovery Systems - Spring House, PA Spring House, Pennsylvania, United States of America
- Sr Eng RD Soft Eng Hyderabad, Andhra Pradesh, India
and 13 more in the company brief.
Technology named in these postings
Named as in use: AWS, AWS services
Asked for as experience: Benchling
Showing up to three quotes for each score. Observed activity is a count of public signals, not a score, and search coverage varies by company. The full account brief for Johnson & Johnson lists every source.
This is not a finding that these companies are inactive. Their account briefs show what we searched and any related activity we recorded as context.
Report new information
Tell us about a public source we missed, or a correction to a company's entry. We only use information anyone can read: company releases, filings, results materials, partner announcements and similar. Nothing you send appears on the radar automatically. We check every report and include what holds up in the next quarterly refresh.
How the scores work. Scores follow Ortent's rubric, summarised on the method page. Only evidence dated inside the window counts. A page with no printed date counts only when its own content dates it, and the quote shows that range. Job adverts, vendor marketing and private knowledge never count towards a score; job adverts appear only as observed activity. For this radar, process and CMC development are grouped with manufacturing and excluded from the research-lab theme. The full method and a brief for each company are on the method page.
Status. Ortent built and reviewed this research; it has not been independently validated. The radar does not predict who will buy, and it does not measure how mature a company's operations are.
Disclosure. Andrew Wyatt, Ortent's principal, was Chief Growth Officer at Sapio Sciences, a lab software company, until April 2026. He has no current relationship with, or financial interest in, Sapio or any other supplier.
Clarity when it counts.
For a board, advisory or fractional engagement, or a working call on the next stage, send a note. Thirty minutes is usually enough to test fit.
Request a 30-minute intro call